Background: The association between tumour measurements and survival has been studied
extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We …

Introduction This study aimed to investigate real-world evidence for efficacy and safety of
durvalumab consolidation (DC) after chemoradiotherapy (CRT) in patients with unresectable …

Background An elevated peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is
a negative prognostic marker for patients with non-small cell lung cancer (NSCLC) receiving …

Categorizations of best response observed at week 8 (between week 3 and 14) of first‐line
treatment in two studies of bevacizumab plus chemotherapy in Western (878 patients) and …

Objectives Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been
limited by the lack of a definitive predictive biomarker. In patients with metastatic melanoma …

Background High TMB is predictive of PFS benefit with anti-PD-(L) 1±anti-CTLA-4 therapy in
mNSCLC. Preliminary results from MYSTIC (NCT02453282), an open-label, Phase III trial of …

Objectives To compare the rate disparity between outcomes (overall survival (OS),
progression-free survival (PFS), and safety) of concurrent chemoradiation (cCRT) followed …

PURPOSE The prediction of clinical outcomes for patients with cancer is central to precision
medicine and the design of clinical trials. We developed and validated machine-learning …

Importance Standard of care for unresectable locally advanced non–small cell lung cancer
(NSCLC) involves definitive chemoradiotherapy followed by maintenance therapy with …

Abstract Introduction/Background Durvalumab is a programmed cell death ligand 1 (PD-L1)
inhibitor indicated for stage III, unresectable non-small cell lung cancer (NSCLC) …